Trevor M. Polischuck, Ph.D. Public Equity Partner, OrbiMed Advisors LLC, updates on the Worldwide Healthcare Trust PLC.
InterMune doubled after reporting positive results from a Phase III clinical trial, called ASCEND. Medivation was a detractor as investors took some profits after the company gave underwhelming 2014 sales guidance.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.
To request emailed copies of monthly fact sheets and other relevant information, please register below.